Medscape covers trial results linking an experimental medication to a major drop in obstructive sleep apnea severity. Tap through for the drug and the data.
Recap by typeshit. Full story at Medscape.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
Rosario in Paris says the team's four AI-designed peptides looked right on paper but none reached the binding affinity they wanted, ending work begun in February.
Endpoints News
Corxel is the second drug developer in two weeks to choose a blank-check merger to go public, a route that had fallen out of favor.
Loading…